STRUCTURAL HEART
CoreValve Evolut-R TAVR (26mm) via Percutaneous Femoral Access – April 2016

An 83 year-old female presented with worsening dyspnea on exertion– NYHA class III and fatigue, with a history of hypertension, Atrial Flutter s/p PPM, moderate COPD, Septal Hypertrophy s/p ablation, kyphosis, and Rt. Breast CA s/p radiation. TTE revealed severe AS, peak/mean aortic gradient = 79/49 mmHg, AVA = 0.5 sq cm, aortic peak velocity = 4.4 m/sec and LVEF 57%. CT angio showed minimum diameters of 0.8 x 0.9 cm for right and 0.8 x 0.9 cm for left common femoral arteries and aortic annulus of 2.4 X 1.8 cm (average 2.1 cm). The STS risk mortality is 5.8% and the Logistic Euroscore mortality is 14.7%. Patient was determined to be high risk for surgical AVR due to COPD and frailty. Patient is now planned for Evolut-R CoreValve TAVR (26mm) via percutaneous femoral access under conscious sedation.

53:00

comments

Leave Your Comments

suggestion
Suggestions
Valve-in-Valve TAVR with 26mm SAPIEN-3 – March 2019
Views247

79 year old man presents with worsening exertional dyspnea (NYHA Class III) for the last 3 months. Patient has required […]


50:31
Valve-in-Valve TAVR with 29mm Evolut-R CoreValve – January 2019
Views467

79 year old man presents with progressive exertional dyspnea (NYHA Class III) for the last 2 months.


1:07:06
TAVR 29mm Sapien-3 – November 2018
Tags:
Views670

96 year old male presents with progressive exertional dyspnea (NYHA Class III) for the last 4 months.


49:42
TAVR in a Patient with Prior Mitral Valve Replacement – September 2018
Tags: |
Views649

87 year old female presents with progressive exertional dyspnea (NYHA Class III) for the last 3 months.